TWI621619B - 乙炔基衍生物 - Google Patents

乙炔基衍生物 Download PDF

Info

Publication number
TWI621619B
TWI621619B TW105124484A TW105124484A TWI621619B TW I621619 B TWI621619 B TW I621619B TW 105124484 A TW105124484 A TW 105124484A TW 105124484 A TW105124484 A TW 105124484A TW I621619 B TWI621619 B TW I621619B
Authority
TW
Taiwan
Prior art keywords
methyl
phenyl
pyrimidine
trione
phenylethynyl
Prior art date
Application number
TW105124484A
Other languages
English (en)
Chinese (zh)
Other versions
TW201718589A (zh
Inventor
喬治 傑許柯
費歐恩 歐哈拉
珍 馬可 帕蘭卻爾
安東尼歐 瑞奇
丹尼爾 路荷
艾瑞克 維拉
Original Assignee
赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赫孚孟拉羅股份公司 filed Critical 赫孚孟拉羅股份公司
Publication of TW201718589A publication Critical patent/TW201718589A/zh
Application granted granted Critical
Publication of TWI621619B publication Critical patent/TWI621619B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW105124484A 2015-08-03 2016-08-02 乙炔基衍生物 TWI621619B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179550 2015-08-03
??15179550.7 2015-08-03

Publications (2)

Publication Number Publication Date
TW201718589A TW201718589A (zh) 2017-06-01
TWI621619B true TWI621619B (zh) 2018-04-21

Family

ID=53776452

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105124484A TWI621619B (zh) 2015-08-03 2016-08-02 乙炔基衍生物

Country Status (20)

Country Link
US (1) US10011607B2 (enExample)
EP (1) EP3331882B1 (enExample)
JP (1) JP6975511B2 (enExample)
KR (1) KR20180030857A (enExample)
CN (1) CN107667107B (enExample)
AR (1) AR105556A1 (enExample)
AU (1) AU2016302696B2 (enExample)
BR (1) BR112017023951A2 (enExample)
CA (1) CA2983908A1 (enExample)
CL (1) CL2018000278A1 (enExample)
CO (1) CO2017011010A2 (enExample)
IL (1) IL255103B (enExample)
MX (1) MX2018001486A (enExample)
PE (1) PE20180357A1 (enExample)
PH (1) PH12018500247A1 (enExample)
RU (1) RU2722014C9 (enExample)
TW (1) TWI621619B (enExample)
UA (1) UA120888C2 (enExample)
WO (1) WO2017021384A1 (enExample)
ZA (1) ZA201707015B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718536A (zh) 2015-08-03 2017-06-01 必治妥美雅史谷比公司 可作為ＴＮＦα調節劑之雜環化合物
CN108026050B (zh) 2015-08-03 2021-04-30 格兰马克药品股份有限公司 作为RORγ调节剂的新型化合物
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
AR117469A1 (es) 2018-12-21 2021-08-11 Merck Patent Gmbh Derivados de alquino disustituidos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015044075A1 (en) * 2013-09-25 2015-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010314891A1 (en) * 2009-11-06 2012-06-07 Vanderbilt University Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
EA023146B1 (ru) * 2011-04-26 2016-04-29 Ф.Хоффманн-Ля Рош Аг Производные пиразолидин-3-она
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
SI3110802T1 (sl) * 2014-02-25 2019-01-31 F. Hoffmann-La Roche Ag Derivati etinila

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015044075A1 (en) * 2013-09-25 2015-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives

Also Published As

Publication number Publication date
AU2016302696A1 (en) 2017-11-02
AR105556A1 (es) 2017-10-18
ZA201707015B (en) 2018-11-28
RU2018105872A3 (enExample) 2019-12-26
BR112017023951A2 (pt) 2018-07-24
IL255103A0 (en) 2017-12-31
CL2018000278A1 (es) 2018-07-06
US20180127429A1 (en) 2018-05-10
CN107667107A (zh) 2018-02-06
WO2017021384A1 (en) 2017-02-09
US10011607B2 (en) 2018-07-03
CO2017011010A2 (es) 2018-02-09
AU2016302696B2 (en) 2020-05-07
RU2018105872A (ru) 2019-09-05
HK1246790A1 (zh) 2018-09-14
CA2983908A1 (en) 2017-02-09
JP6975511B2 (ja) 2021-12-01
IL255103B (en) 2020-01-30
CN107667107B (zh) 2021-05-18
EP3331882B1 (en) 2020-04-29
RU2722014C2 (ru) 2020-05-26
RU2722014C9 (ru) 2020-10-22
PE20180357A1 (es) 2018-02-21
UA120888C2 (uk) 2020-02-25
JP2018522037A (ja) 2018-08-09
KR20180030857A (ko) 2018-03-26
TW201718589A (zh) 2017-06-01
MX2018001486A (es) 2018-03-15
EP3331882A1 (en) 2018-06-13
PH12018500247A1 (en) 2018-08-13

Similar Documents

Publication Publication Date Title
US11964961B2 (en) Heteroaromatic compounds and their use as dopamine D1 ligands
US12240812B2 (en) Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP2570411A1 (en) Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity
TWI621619B (zh) 乙炔基衍生物
EP3134405B1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
TW201524963A (zh) 乙炔基衍生物
TWI605042B (zh) 乙炔基衍生物
HK1246790B (zh) 乙炔基衍生物
HK40051501A (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
HK40051501B (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees